COMMUNIQUÉS West-GlobeNewswire

Advantis Corp. Expects Quarterly Revenue Records Throughout 2018

18/12/2017 - 15:15

Newport Beach, CA , Dec. 18, 2017 (GLOBE NEWSWIRE) -- ADVANTIS CORPORATION (OTC PINK: ADVT ) CEO, Darren Cherry, took a moment to review the progress the company has made this year, and lays out an achievable set of [...]

Orion Corporation: Managers' transactions - Huhta-Koivisto Tero

18/12/2017 - 15:00

ORION CORPORATION MANAGERS' TRANSACTIONS 18 DECEMBER 2017 at 16.00 EET Orion Corporation: Managers' transactions - Huhta-Koivisto Tero Orion Corporation has received the following disclosure under Market Abuse [...]

La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis

18/12/2017 - 15:00

SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ: LJPC ) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC‑401 (synthetic human [...]

athenahealth to Present at the 36th Annual J.P. Morgan Healthcare Conference

18/12/2017 - 15:00

WATERTOWN, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- athenahealth, Inc. (NASDAQ: ATHN ), a leading provider of network-enabled services for hospital and ambulatory clients nationwide, today announced that Jonathan Bush, [...]

Orion Corporation: Managers' transactions - Huhta-Koivisto Kalle

18/12/2017 - 14:51

ORION CORPORATION MANAGERS' TRANSACTIONS 18 DECEMBER 2017 at 15.50 EET Orion Corporation: Managers' transactions - Huhta-Koivisto Kalle Orion Corporation has received the following disclosure under Market Abuse [...]

Orion Corporation: Managers' transactions - Huhta-Koivisto Esko kuolinpesä

18/12/2017 - 14:46

ORION CORPORATION MANAGERS' TRANSACTIONS 18 DECEMBER 2017 at 15.45 EET Orion Corporation: Managers' transactions - Huhta-Koivisto Esko kuolinpesä Orion Corporation has received the following disclosure under Market [...]

RespireRx Pharmaceuticals Inc. Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development

18/12/2017 - 14:45

Glen Rock, N.J., Dec. 18, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that a paper detailing the neurobiologic safety of the ampakine [...]

United Health Products Completes Multiple FDA Required Tests for HemoStyp®

18/12/2017 - 14:30

HENDERSON, Nev., Dec. 18, 2017 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today [...]

EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment

18/12/2017 - 14:30

WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG ) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform technologies for [...]

Ultragenyx Sells Priority Review Voucher for $130 million

18/12/2017 - 14:30

NOVATO, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today [...]

New Biomarker Data Supports Direct Link between VB-111’s Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients

18/12/2017 - 14:28

TEL AVIV, Israel, Dec. 18, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), announced new biomarker data supporting the direct link between lead asset VB-111’s dual mechanism of action and clinical effect on [...]

Novo Nordisk A/S: Share repurchase programme

18/12/2017 - 14:22

Bagsværd, Denmark, 18 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Horizon Health Network and Service New Brunswick extend Allscripts Sunrise™ commitment

18/12/2017 - 14:01

RICHMOND, British Columbia, Dec. 18, 2017 (GLOBE NEWSWIRE) -- In the fourth quarter of 2017, Horizon Health Network and Service New Brunswick extended its contract term with Allscripts through 2024, to further clinical [...]

IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 29, 2017

18/12/2017 - 14:00

BETHESDA, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), adjourned again the voting for Proposals Three and Four from its Notice of Annual Meeting of Shareholders, dated [...]

Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma

18/12/2017 - 14:00

SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that [...]

Uptick Newswire “Stock Day” Interviews CEO of Lexaria on Cannabis Related Products and Recent Bioscience Patents

18/12/2017 - 14:00

Phoenix, AZ, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Uptick Newswire is the sole producer of the Uptick Network “Stock Day” Podcast and after airing back in January 2016 CEO and host Everett Jolly has interviewed hundreds of [...]

Samumed Doses First Patient in Phase 1 Trial of SM04690 for Treatment of Degenerative Disc Disease

18/12/2017 - 14:00

SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first degenerative disc disease (DDD) patient in its Phase 1 trial of SM04690, a small molecule Wnt pathway inhibitor [...]

CytomX Therapeutics Added to NASDAQ Biotechnology Index

18/12/2017 - 14:00

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX ), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of [...]

Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma

18/12/2017 - 14:00

BERKELEY, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the first patient in its Phase 1/ [...]